BioLine RX Ltd
Change company Symbol lookup
Select an option...
BLRX BioLine RX Ltd
BLPH Bellerophon Therapeutics Inc
BLNK Blink Charging Co
CTXS Citrix Systems Inc
AFHIF Atlas Financial Holdings Inc
RIOCF RioCan Real Estate Investment Trust
OMP Oasis Midstream Partners LP
GMED Globus Medical Inc
TSN Tyson Foods Inc
VOO Vanguard S&P 500 ETF

Health Care : Biotechnology | Small Cap Value
Based in Israel
Company profile

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees


Last Trade
-0.18 (-6.10%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: Mesa Air stock soars to pre-COVID highs after BofA double upgrade to buy

11:45 am ET February 17, 2021 (MarketWatch)

Tomi Kilgore

Analyst Andrew Didora boosts stock price target by more than 7 times to $15

Shares of Mesa Air Group Inc. soared to pre-COVID highs, after BofA Securities analyst Andrew Didora swung to bullish from bearish, saying the regional air carrier is well positioned to capitalize on the return to travel.

The stock (MESA) ran up 8.1% in midday trading, and has now jumped 54.0% over the past week. The stock has rocketed more than fivefold (up 438%) from its post-COVID closing low of $2.13 on April 3, to trade at the highest levels seen since December 2018, which was a year before the virus outbreak was believed to have started (

The stock's rally Wednesday comes while the U.S. Global Jets exchange-traded fund (JETS) edged up 0.3% while the S&P 500 index fell 0.6%.

Didora raised his rating on Mesa by two notches to buy from underperform, while boosting his stock price target more than sevenfold to $15 from $2.

He said Mesa is a "large beneficiary" of the U.S. government's support of the airline industry, as it received more than $140 million in grant funds and a $195 million load to refinance higher debt costs.

And with long-term contracts at larger carriers United Airlines Holdings Inc. (UAL) and American Airlines Group Inc. (AAL), "we believe Mesa is now well positioned to help its partners capitalize on a return to domestic travel, particularly as the network airlines should focus more on hub traffic," Didora wrote in a note to clients.

Separately, Didora was also upbeat about Mesa's recent partnership with United in placing a $1 billion order for all-electric vertical takeoff and landing aircraft (eVTOL) from Archer Aviation Inc.

Archer announced last week it was going public through a merger with special-purpose acquisition company Atlas Crest Investment Corp. (ACIC) Mesa said at the time that it agreed to pay $5 million to buy 500,000 Atlas shares (, and that it will receive a warrant exercisable to for 2.9 million Archer shares.

Atlas Crest's stock surged 8.8% in midday trading.

Didora said that investment "gives Mesa equity exposure to a high-growth segment to balance out its more stable regional airline model."

Mesa's stock has more than doubled (up 127.8%) over the past three months, while the Jets ETF has advanced 15.1% and the S&P 500 has gained 8.3%.

-Tomi Kilgore; 415-439-6400;


(END) Dow Jones Newswires

February 17, 2021 11:45 ET (16:45 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.